Evidence map›Paper›PMID 38681116›Full record

ArticleOral oncology reports2024

RNA-binding protein HuR reprograms immune T cells and promotes oral squamous cell carcinoma.

Mrinmoyee Majumder, Harinarayanan Janakiraman, Paramita Chakraborty, Anitha Vijayakumar, Sari Mayhue, Hong Yu, Toros Dincman, Romeo Martin, Elizabeth O'Quinn, Shikhar Mehrotra and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mrinmoyee MajumderDepartment of Biochemistry and Molecular Biology, USA.
Harinarayanan JanakiramanDepartment of Biochemistry and Molecular Biology, USA.
Paramita ChakrabortyDepartment of Surgery, College of Medicine, USA.
Anitha VijayakumarDepartment of Biochemistry and Molecular Biology, USA.
Sari MayhueDepartment of Biochemistry and Molecular Biology, USA.
Hong YuOral Health Sciences, College of Dental Medicine, USA.
Toros DincmanDepartment of Haematology and Oncology, College of Medicine, USA.
Romeo MartinHollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Elizabeth O'QuinnHollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Shikhar MehrotraDepartment of Surgery, College of Medicine, USA.
Viswanathan PalanisamyDepartment of Biochemistry and Molecular Biology, USA.

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
T-COHR: Training in Craniofacial and Oral Health ResearchT32DE017551 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YAO, HAI · 2006 to 2025
$10.3M
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticityR01DE030013 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MEHROTRA, SHIKHAR, PALANISAMY, VISWANATHAN · 2020 to 2024
$2.3M
Targeting of RNA-binding protein FXR1 in HNSCCR21DE032461 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PALANISAMY, VISWANATHAN · 2023 to 2023
$419k
NCI NIH HHS P30 CA138313NIDCR NIH HHS R01 DE030013NIDCR NIH HHS R21 DE032461NIDCR NIH HHS T32 DE017551
6 · The paper itself

Abstract

Hu Antigen R, also known as ELAVL1 (HuR), is a key posttranscriptional regulator in eukaryotic cells. HuR overexpression promotes several malignancies, including head and neck squamous cell carcinoma (HNSCC). However, its immune dysfunction-associated tumorigenesis pathways remain unknown. We examined HuR's effects on oral malignancies and immune cell function in vitro and in vivo using oral carcinoma cells and transgenic HuR knockout (KO) mice. CRISPR/Cas9-mediated HuR deletion in mice syngeneic oral cancer cells eliminated colony formation and tumor development. HuR-KO tumors had a lower tumor volume, fewer CD4

Indexed as

Antitumor effectsImmune infiltrationOral squamous cell carcinomaPyrvinium pamoateRNA-Binding proteinsT-regulatory cells

Identifiers

PMID38681116
PMCPMC11044901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.